復宏漢霖(02696.HK):斯魯利單抗注射液聯合重組抗EGFR人源化單克隆抗體注射液HLX07治療實體瘤的2期臨試申請獲NMPA批准
格隆匯12月20日丨復宏漢霖(02696.HK)發佈公吿,近日,公司自主開發的斯魯利單抗注射液(重組抗PD-1人源化單克隆抗體注射液)(“斯魯利單抗注射液”)聯合重組抗EGFR人源化單克隆抗體注射液HLX07用於治療實體瘤的2期臨牀試驗申請(IND)獲國家藥品監督管理局(“NMPA”)批准。公司擬於條件具備後於中國大陸(不包括港澳台地區)啟動該治療方案用於相關適應症的2期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.